OLIPASS Corporation
OLIPASS Corporation, a biotech company, focuses on developing therapeutic products in South Korea. The company develops its products using its novel PNA based technologies. Its products pipeline includes SCN9A, a product candidate that is in Phase II clinical trials for the treatment of pain. The company also develops PCSK9 for the treatment of hyper cholesterolemia; VEGF for the treatment of AMD… Read more
OLIPASS Corporation (244460) - Net Assets
Latest net assets as of December 2024: ₩11.86 Billion KRW
Based on the latest financial reports, OLIPASS Corporation (244460) has net assets worth ₩11.86 Billion KRW as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩26.28 Billion) and total liabilities (₩14.42 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩11.86 Billion |
| % of Total Assets | 45.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.71% |
| 10-Year Change | N/A |
| Growth Volatility | 170.87 |
OLIPASS Corporation - Net Assets Trend (2016–2024)
This chart illustrates how OLIPASS Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OLIPASS Corporation (2016–2024)
The table below shows the annual net assets of OLIPASS Corporation from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩11.86 Billion | +375.49% |
| 2023-12-31 | ₩2.49 Billion | -76.16% |
| 2022-12-31 | ₩10.46 Billion | -66.04% |
| 2021-12-31 | ₩30.80 Billion | -29.09% |
| 2020-12-31 | ₩43.44 Billion | +125.29% |
| 2019-12-31 | ₩19.28 Billion | +155.41% |
| 2018-12-31 | ₩-34.80 Billion | +17.67% |
| 2017-12-31 | ₩-42.28 Billion | +28.98% |
| 2016-12-31 | ₩-59.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to OLIPASS Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12928352490000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩236.27 Billion | 1992.62% |
| Total Equity | ₩11.86 Billion | 100.00% |
OLIPASS Corporation Competitors by Market Cap
The table below lists competitors of OLIPASS Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Spentex Industries Limited
NSE:SPENTEX
|
$2.80 Million |
|
RPM Automotive Group Ltd
AU:RPM
|
$2.80 Million |
|
INTERDIGITAL
BE:IDI
|
$2.80 Million |
|
GUNGNIR RES INC.
F:AMO1
|
$2.80 Million |
|
BRADDA HEAD LITHIUM O.N.
F:8CD1
|
$2.80 Million |
|
Melkior Resources Inc
PINK:MKRIF
|
$2.79 Million |
|
MICube Solution Inc
KQ:373170
|
$2.79 Million |
|
Prima Cakrawala Abadi PT
JK:PCAR
|
$2.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OLIPASS Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,493,718,210 to 11,857,420,410, a change of 9,363,702,200 (375.5%).
- Net loss of 5,316,547,950 reduced equity.
- New share issuances of 6,500,003,570 increased equity.
- Other factors increased equity by 8,180,246,580.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.32 Billion | -44.84% |
| Share Issuances | ₩6.50 Billion | +54.82% |
| Other Changes | ₩8.18 Billion | +68.99% |
| Total Change | ₩- | 375.49% |
Book Value vs Market Value Analysis
This analysis compares OLIPASS Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩-3451.65 | ₩1651.00 | x |
| 2017-12-31 | ₩-2449.78 | ₩1651.00 | x |
| 2018-12-31 | ₩-1843.59 | ₩1651.00 | x |
| 2019-12-31 | ₩809.23 | ₩1651.00 | x |
| 2020-12-31 | ₩1760.11 | ₩1651.00 | x |
| 2021-12-31 | ₩1177.48 | ₩1651.00 | x |
| 2022-12-31 | ₩356.69 | ₩1651.00 | x |
| 2023-12-31 | ₩808.34 | ₩1651.00 | x |
| 2024-12-31 | ₩2521.25 | ₩1651.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OLIPASS Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -44.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -703.22%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 2.22x
- Recent ROE (-44.84%) is above the historical average (-128.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -2101252.55% | 0.00x | 0.00x | ₩-42.80 Billion |
| 2017 | 0.00% | 15283.64% | 0.00x | 0.00x | ₩21.33 Billion |
| 2018 | 0.00% | -5540.01% | 0.01x | 0.00x | ₩-23.57 Billion |
| 2019 | -236.68% | -2676.37% | 0.03x | 2.84x | ₩-47.57 Billion |
| 2020 | -55.67% | -845.35% | 0.04x | 1.57x | ₩-28.53 Billion |
| 2021 | -81.59% | -2950.84% | 0.02x | 1.50x | ₩-28.21 Billion |
| 2022 | -231.02% | -1052.59% | 0.09x | 2.38x | ₩-25.21 Billion |
| 2023 | -502.95% | -220.72% | 0.42x | 5.46x | ₩-12.79 Billion |
| 2024 | -44.84% | -703.22% | 0.03x | 2.22x | ₩-6.50 Billion |
Industry Comparison
This section compares OLIPASS Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OLIPASS Corporation (244460) | ₩11.86 Billion | 0.00% | 1.22x | $2.80 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |